methyl (R,E)-7-(3-(4-fluorophenyl)-5-((4-hydroxyphenyl)carbamoyl)-1-isopropyl-4-phenyl-1H-pyrrol-2-yl)-3-hydroxy-5-oxohept-6-enoate | 950599-53-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: methyl (R,E)-7-(3-(4-fluorophenyl)-5-((4-hydroxyphenyl)carbamoyl)-1-isopropyl-4-phenyl-1H-pyrrol-2-yl)-3-hydroxy-5-oxohept-6-enoate
• CAS: 950599-53-8
• 化学式: C₃₄H₃₃FN₂O₆
• 分子量: 584.644
• InChiKey: PXVAIYZGQNACPG-GHUONELISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.4
• 重原子数：
  43.0
• 可旋转键数：
  11.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  117.86
• 氢给体数：
  3.0
• 氢受体数：
  7.0

反应信息

• 作为反应物：
  描述：

  methyl (R,E)-7-(3-(4-fluorophenyl)-5-((4-hydroxyphenyl)carbamoyl)-1-isopropyl-4-phenyl-1H-pyrrol-2-yl)-3-hydroxy-5-oxohept-6-enoate 在 palladium on activated charcoal sodium tetrahydroborate 、 二乙基甲氧基硼烷 、 氢气 、 溶剂黄146 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 5.0h， 生成 methyl (3R,5R)-7-(3-(4-fluorophenyl)-5-((4-hydroxyphenyl)carbamoyl)-1-isopropyl-4-phenyl-1H-pyrrol-2-yl)-3,5-dihydroxyheptanoate
  参考文献：
  名称：

  Design and synthesis of hepatoselective, pyrrole-based HMG-CoA reductase inhibitors

  摘要：

  This manuscript describes the design and synthesis of a series of pyrrole-based inhibitors of HMG-CoA reductase for the treatment of hypercholesterolemia. Analogs were optimized using structure-based design and physical property considerations resulting in the identification of 44, a hepatoselective HMG-CoA reductase inhibitor with excellent acute and chronic efficacy in a pre-clinical animal models. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.05.096
• 作为产物：
  描述：

  4-(4-fluorophenyl)-5-formyl-1-isopropyl-3-phenyl-1H-pyrrole-2-carbonyl chloride 在 氢氟酸 、 三乙胺 作用下， 以 四氢呋喃 、 甲苯 、 乙腈 为溶剂， 反应 62.0h， 生成 methyl (R,E)-7-(3-(4-fluorophenyl)-5-((4-hydroxyphenyl)carbamoyl)-1-isopropyl-4-phenyl-1H-pyrrol-2-yl)-3-hydroxy-5-oxohept-6-enoate
  参考文献：
  名称：

  Design and synthesis of hepatoselective, pyrrole-based HMG-CoA reductase inhibitors

  摘要：

  This manuscript describes the design and synthesis of a series of pyrrole-based inhibitors of HMG-CoA reductase for the treatment of hypercholesterolemia. Analogs were optimized using structure-based design and physical property considerations resulting in the identification of 44, a hepatoselective HMG-CoA reductase inhibitor with excellent acute and chronic efficacy in a pre-clinical animal models. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.05.096